<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00420342</url>
  </required_header>
  <id_info>
    <org_study_id>91507</org_study_id>
    <secondary_id>310522</secondary_id>
    <nct_id>NCT00420342</nct_id>
  </id_info>
  <brief_title>Effects of Angeliq and Prempro on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension</brief_title>
  <official_title>A Double Blind, Randomized, Active-control Study to Evaluate Effects of Drospirenone/Estradiol (Angeliq) and Medroxyprogesterone Acetate/Conjugated Equine Estrogen (Prempro) on Blood Pressure and Sodium Sensitivity in Postmenopausal Women With Prehypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare the effects of treatment of two different
      formulations of Angeliq® and Prempro on blood pressure in post-menopausal women with
      prehypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has previously been posted by Berlex, Inc. Berlex, Inc. has been renamed to Bayer
      HealthCare Pharmaceuticals, Inc.Bayer HealthCare Pharmaceuticals, Inc. is the sponsor of the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the full analysis set. The change from baseline means was adjusted for center and baseline SBP.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the per protocol (PP) population. The change from baseline means was adjusted for center and baseline SBP.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The mean change in 24-hr Diastolic Blood Pressure (DBP) from Baseline to Week 8 was calculated for the full analysis set.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Seated systolic and diastolic office cuff blood pressures were taken at each visit; the mean of three readings were used at each timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Systolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Diastolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8</measure>
    <time_frame>8 weeks plus 3 days</time_frame>
    <description>Sodium sensitivity was defined as ≥ 10 mmHg drop in mean arterial pressure, calculated from the office cuff BP values from Day 1 to Day 3. The number of subjects shifting from sodium sensitive at Baseline to sodium resistant at Week 8 or sodium resistant at Baseline to sodium sensitive at Week 8 by treatment group was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 112 mmHg (Posthoc Analysis)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 116 mmHg (Posthoc Analysis)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 120 mmHg (Posthoc Analysis)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 124 mmHg (Posthoc Analysis)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 130 mmHg (Posthoc Analysis)</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">92</enrollment>
  <condition>Postmenopause</condition>
  <condition>Hypertension</condition>
  <condition>Pre-Hypertension</condition>
  <arm_group>
    <arm_group_label>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1.5 mg MPA / 0.3 mg CEE (Prempro)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)</intervention_name>
    <description>SH K 00641 A -Active study medication encapsulated tablet</description>
    <arm_group_label>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)</intervention_name>
    <description>SH K 00641 B - Active study medication encapsulated tablet</description>
    <arm_group_label>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)</intervention_name>
    <description>Active control encapsulated tablet</description>
    <arm_group_label>1.5 mg MPA / 0.3 mg CEE (Prempro)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Postmenopausal women 45 - 65 years old with prehypertension

        Exclusion Criteria:

        - Hormone therapy (estrogen/progestin)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <zip>49079</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arlington</city>
        <state>Virginia</state>
        <zip>22203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2007</study_first_posted>
  <results_first_submitted>October 28, 2009</results_first_submitted>
  <results_first_submitted_qc>January 18, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 20, 2010</results_first_posted>
  <last_update_submitted>May 11, 2015</last_update_submitted>
  <last_update_submitted_qc>May 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pre-Hypertension in Postmenopausal Women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Prehypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Estrogens, Conjugated (USP)</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subject enrollment began on 16-Jan-2007 and lasted over a period of 6 months at 10 study centers in the U.S. There was no enrollment at 2 sites (108 and 110). Site 102 enrolled 14 subjects and site 105 enrolled 56 subjects (28 of whom consented to the sodium sensitivity analysis). All other sites enrolled 7 or fewer subjects.</recruitment_details>
      <pre_assignment_details>Screening involved office cuff BP measurements at 3 visits to evaluate prehypertension. Of the 178 enrolled, 86 subjects were screen failures. The full analysis and safety sets had 90 subjects who took at least 1 dose of study medication (2 subjects did not confirm if they ever took the study medication).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
          <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="P2">
          <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
          <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="P3">
          <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
          <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="33"/>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="29">1 subject did not confirm if she ever took the study medication.</participants>
                <participants group_id="P2" count="32">1 subject did not confirm if she ever took the study medication.</participants>
                <participants group_id="P3" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="31"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
          <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="B2">
          <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
          <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="B3">
          <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
          <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="32"/>
            <count group_id="B3" value="29"/>
            <count group_id="B4" value="90"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="4.6"/>
                    <measurement group_id="B2" value="54.6" spread="5.6"/>
                    <measurement group_id="B3" value="54.1" spread="4.5"/>
                    <measurement group_id="B4" value="55.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Black / African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Smoking history</title>
          <description>Subjects smoking more than 10 cigarettes per day were excluded from the study.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline ambulatory blood pressure</title>
          <description>24-hour mean Ambulatory blood pressure monitoring (ABPM) values at the Baseline visit.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>systolic blood pressure (SBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.4" spread="7.6"/>
                    <measurement group_id="B2" value="120.9" spread="10.4"/>
                    <measurement group_id="B3" value="122.1" spread="11.6"/>
                    <measurement group_id="B4" value="121.4" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure (DBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.4" spread="6.7"/>
                    <measurement group_id="B2" value="73.1" spread="7.6"/>
                    <measurement group_id="B3" value="73.9" spread="8.0"/>
                    <measurement group_id="B4" value="73.1" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline cuff blood pressure</title>
          <description>The baseline SBP was to be between 130 and 139 mmHg and DBP ≤ 89 mmHg. The mean SBP values from 2 of the 3 consecutive office cuff measurements during the screening visits were to have been within 12 mmHg and the mean DBP values within 8 mmHg to confirm stability of the blood pressure.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>systolic blood pressure (SBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133.6" spread="3.2"/>
                    <measurement group_id="B2" value="134.3" spread="2.1"/>
                    <measurement group_id="B3" value="133.7" spread="2.4"/>
                    <measurement group_id="B4" value="133.9" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>diastolic blood pressure (DBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81.5" spread="4.7"/>
                    <measurement group_id="B2" value="81.7" spread="4.0"/>
                    <measurement group_id="B3" value="80.3" spread="5.7"/>
                    <measurement group_id="B4" value="81.2" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>Height, body weight, and arm circumference were measured at the screening visit and body weight was measured at the screening, treatment phase, and follow-up visits. The same scale was used for all body weight measurements. BMI was measured in kg/m^2.</description>
          <units>Kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="5.2"/>
                    <measurement group_id="B2" value="27.6" spread="4.4"/>
                    <measurement group_id="B3" value="27.9" spread="3.4"/>
                    <measurement group_id="B4" value="28.2" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population</title>
        <description>The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the full analysis set. The change from baseline means was adjusted for center and baseline SBP.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary analysis used Full Analysis Set (FAS), which follows ITT principles; no imputation methods used; patients with missing data had no Blood Pressure (BP) values after baseline</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hour SBP From the Ambulatory Blood Pressure Monitoring (ABPM) Measurements in Full Analysis Set (FAS) Population</title>
          <description>The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the full analysis set. The change from baseline means was adjusted for center and baseline SBP.</description>
          <population>Primary analysis used Full Analysis Set (FAS), which follows ITT principles; no imputation methods used; patients with missing data had no Blood Pressure (BP) values after baseline</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="1.49"/>
                    <measurement group_id="O2" value="-0.27" spread="1.35"/>
                    <measurement group_id="O3" value="2.18" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons among all three treatment groups were performed; both DRSP / E2 group vs MPA /CEE, and the two active doses against each other. Null hypotheses were that there were no differences between groups for each of the three pairwise comparison. Analysis of variance model was used, with terms for treatment, center, and baseline BP values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1182</p_value>
            <p_value_desc>0.5 mg DRSP / 1.0 mg E2 vs 1.5 mg MPA / 0.3 mg CEE.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustments made for multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons among all three treatment groups were performed; both DRSP / E2 group vs MPA /CEE, and the two active doses against each other. Null hypotheses were that there were no differences between groups for each of the three pairwise comparison. Analysis of variance model was used, with terms for treatment, center, and baseline BP values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2224</p_value>
            <p_value_desc>2.0 mg DRSP / 1.0 mg E2 vs 1.5mg MPA / 0.3 mg CEE.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustments made for multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons among all three treatment groups were performed; both DRSP / E2 group vs MPA /CEE, and the two active doses against each other. Null hypotheses were that there were no differences between groups for each of the three pairwise comparison. Analysis of variance model was used, with terms for treatment, center, and baseline BP values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6929</p_value>
            <p_value_desc>0.5 mg DRSP / 1.0 mg E2 vs 2.0 mg DRSP / 1.0 mg E2.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustments made for multiple comparisons</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population</title>
        <description>The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the per protocol (PP) population. The change from baseline means was adjusted for center and baseline SBP.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary analysis was Per Protocol Population (PP); no imputation methods used; patients with missing data had no BP values after baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hour SBP From the ABPM Measurements in Per Protocol Population</title>
          <description>The mean change in 24-hr ambulatory systolic blood pressure (SBP) from Baseline to Week 8 was calculated for the per protocol (PP) population. The change from baseline means was adjusted for center and baseline SBP.</description>
          <population>Primary analysis was Per Protocol Population (PP); no imputation methods used; patients with missing data had no BP values after baseline.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.08" spread="1.62"/>
                    <measurement group_id="O2" value="0.06" spread="1.50"/>
                    <measurement group_id="O3" value="2.82" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons among all three treatment groups were performed; both DRSP / E2 group vs MPA /CEE, and the two active doses against each other. Null hypotheses were that there were no differences between groups for each of the three pairwise comparison. Analysis of variance model was used, with terms for treatment, center, and baseline BP values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0702</p_value>
            <p_value_desc>0.5 mg DRSP / 1.0 mg E2 vs 1.5 mg MPA / 0.3 mg CEE.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustments made for multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons among all three treatment groups were performed; both DRSP / E2 group vs MPA /CEE, and the two active doses against each other. Null hypotheses were that there were no differences between groups for each of the three pairwise comparison. Analysis of variance model was used, with terms for treatment, center, and baseline BP values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1980</p_value>
            <p_value_desc>2.0 mg DRSP / 1.0 mg E2 vs 1.5mg MPA / 0.3 mg CEE.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustments made for multiple comparisons</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Pairwise comparisons among all three treatment groups were performed; both DRSP / E2 group vs MPA /CEE, and the two active doses against each other. Null hypotheses were that there were no differences between groups for each of the three pairwise comparison. Analysis of variance model was used, with terms for treatment, center, and baseline BP values.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5777</p_value>
            <p_value_desc>0.5 mg DRSP / 1.0 mg E2 vs 2.0 mg DRSP / 1.0 mg E2.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>No adjustments made for multiple comparisons</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements</title>
        <description>The mean change in 24-hr Diastolic Blood Pressure (DBP) from Baseline to Week 8 was calculated for the full analysis set.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hour DBP From the ABPM Measurements</title>
          <description>The mean change in 24-hr Diastolic Blood Pressure (DBP) from Baseline to Week 8 was calculated for the full analysis set.</description>
          <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="1.02"/>
                    <measurement group_id="O2" value="-0.91" spread="0.93"/>
                    <measurement group_id="O3" value="0.57" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough</title>
        <description>Seated systolic and diastolic office cuff blood pressures were taken at each visit; the mean of three readings were used at each timepoint.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Office Cuff SBP and DBP at Trough</title>
          <description>Seated systolic and diastolic office cuff blood pressures were taken at each visit; the mean of three readings were used at each timepoint.</description>
          <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic Blood Pressure (SBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.25" spread="1.54"/>
                    <measurement group_id="O2" value="-6.02" spread="1.44"/>
                    <measurement group_id="O3" value="-4.20" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic Blood Pressure (DBP)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.13"/>
                    <measurement group_id="O2" value="-0.36" spread="1.05"/>
                    <measurement group_id="O3" value="0.33" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements</title>
        <description>Systolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle)</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline; number of subjects analyzed was 27 in the 0.5mg DRSP group for nighttime values</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough SBP From the ABPM Measurements</title>
          <description>Systolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle)</description>
          <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline; number of subjects analyzed was 27 in the 0.5mg DRSP group for nighttime values</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.08" spread="1.49"/>
                    <measurement group_id="O2" value="-1.06" spread="1.35"/>
                    <measurement group_id="O3" value="1.53" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="1.99"/>
                    <measurement group_id="O2" value="1.64" spread="1.75"/>
                    <measurement group_id="O3" value="3.97" spread="2.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.91" spread="1.99"/>
                    <measurement group_id="O2" value="-1.48" spread="1.81"/>
                    <measurement group_id="O3" value="-1.51" spread="2.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements</title>
        <description>Diastolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle)</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline; number of subjects analyzed was 27 in the 0.5mg DRSP group for nighttime values</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean Day Time, Mean Nighttime and Mean Trough DBP From the ABPM Measurements</title>
          <description>Diastolic blood pressure means were calculated during the intervals daytime (6 AM - 10 PM); nighttime (10 PM - 6 AM), and trough (mean of last 5 measurements in the 24-hour cycle)</description>
          <population>Primary analysis used FAS; no imputation methods used; patients with missing data had no BP values after baseline; number of subjects analyzed was 27 in the 0.5mg DRSP group for nighttime values</population>
          <units>mmHg</units>
          <param>Median</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>mean daytime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.95" spread="1.03"/>
                    <measurement group_id="O2" value="-1.56" spread="0.93"/>
                    <measurement group_id="O3" value="0.17" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean nighttime</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" spread="1.48"/>
                    <measurement group_id="O2" value="0.67" spread="1.30"/>
                    <measurement group_id="O3" value="1.75" spread="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mean trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.04" spread="1.46"/>
                    <measurement group_id="O2" value="-1.13" spread="1.32"/>
                    <measurement group_id="O3" value="-0.30" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8</title>
        <description>Sodium sensitivity was defined as ≥ 10 mmHg drop in mean arterial pressure, calculated from the office cuff BP values from Day 1 to Day 3. The number of subjects shifting from sodium sensitive at Baseline to sodium resistant at Week 8 or sodium resistant at Baseline to sodium sensitive at Week 8 by treatment group was reported.</description>
        <time_frame>8 weeks plus 3 days</time_frame>
        <population>FAS subjects from the one site which performed the sodium sensitivity analysis</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Are Sodium Sensitive at Baseline and Week 8</title>
          <description>Sodium sensitivity was defined as ≥ 10 mmHg drop in mean arterial pressure, calculated from the office cuff BP values from Day 1 to Day 3. The number of subjects shifting from sodium sensitive at Baseline to sodium resistant at Week 8 or sodium resistant at Baseline to sodium sensitive at Week 8 by treatment group was reported.</description>
          <population>FAS subjects from the one site which performed the sodium sensitivity analysis</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 112 mmHg (Posthoc Analysis)</title>
        <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 112 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 112 mmHg (Posthoc Analysis)</title>
          <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
          <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 112 mmHg</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="8.2"/>
                    <measurement group_id="O2" value="-1.9" spread="9.1"/>
                    <measurement group_id="O3" value="1.4" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 116 mmHg (Posthoc Analysis)</title>
        <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 116 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 116 mmHg (Posthoc Analysis)</title>
          <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
          <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 116 mmHg</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="7.9"/>
                    <measurement group_id="O2" value="-2.2" spread="9.6"/>
                    <measurement group_id="O3" value="2.0" spread="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 120 mmHg (Posthoc Analysis)</title>
        <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 120 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 120 mmHg (Posthoc Analysis)</title>
          <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
          <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 120 mmHg</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="8.1"/>
                    <measurement group_id="O2" value="-3.7" spread="9.9"/>
                    <measurement group_id="O3" value="1.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 124 mmHg (Posthoc Analysis)</title>
        <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 124 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 124 mmHg (Posthoc Analysis)</title>
          <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
          <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 124 mmHg</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="6.9"/>
                    <measurement group_id="O2" value="-4.4" spread="10.4"/>
                    <measurement group_id="O3" value="1.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 130 mmHg (Posthoc Analysis)</title>
        <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
        <time_frame>Baseline to Week 8</time_frame>
        <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 130 mmHg</population>
        <group_list>
          <group group_id="O1">
            <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O2">
            <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
            <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
          <group group_id="O3">
            <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
            <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 8 in Mean 24-hours ABPM SBP Values, Baseline Mean &gt; 130 mmHg (Posthoc Analysis)</title>
          <description>Mean 24-hour ABPM SBP values were calculated in posthoc subgroup analyses for the following subgroups: Baseline mean 24-hour SBP from ABPM &gt;112 mmHg, &gt;116 mmHg, &gt;120 mmHg, &gt;124 mmHg, and &gt;130 mmHg.</description>
          <population>FAS population, for patients with baseline 24-hour ABPM means &gt; 130 mmHg</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="10.1"/>
                    <measurement group_id="O2" value="-4.0" spread="12.5"/>
                    <measurement group_id="O3" value="1.0" spread="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>0.5mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
          <description>0.5 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="E2">
          <title>2.0mg DRSP / 1.0mg E2 (Angeliq, BAY86-4891)</title>
          <description>2.0 mg drospirenone/1.0 mg 17β-estradiol for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
        <group group_id="E3">
          <title>1.5 mg MPA / 0.3 mg CEE (Prempro)</title>
          <description>1.5 mg medroxyprogesterone acetate/0.3 mg conjugated equine estrogen for 8 weeks (8 weeks plus 3 days for sodium sensitivity subjects)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>(A). PI will provide copy to Sponsor sixty (60) days. Sponsor will have thirty (30) days to review and provide feedback. (B). If proposed publication presents material adverse effect on Sponsor's confidentiality information, then PI shall delay or prevent such publication. (C) In multi-center trial, the investigative data will be pooled and published as a collaborative effort with consent from all parties including the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size, as this was a pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Therapeutic Area Head</name_or_title>
      <organization>BAYER</organization>
      <email>clinical-trials-contact@bayerhealthcare.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

